INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 30 September 2011
|
Total net assets |
£91.2m |
|
NAV per share |
163.5p |
|
Share price |
145.5p |
|
Total value of unquoted investments |
£23.7m |
|
Total number of portfolio companies |
68 |
|
Cash |
(7)% NAV |
|
Cash committed and reserved to unquoted investments |
(10)% NAV |
|
Portfolio companies with < 1 year of cash |
12% NAV |
Top Ten Holdings
|
Company Name |
% NAV |
|
Cadent |
6.1 |
|
Amgen |
6.0 |
|
Pharmasset |
5.4 |
|
Teva |
5.0 |
|
Gilead Sciences |
4.5 |
|
Insulet |
4.2 |
|
Shire |
3.9 |
|
Micromet |
3.5 |
|
Celgene |
3.5 |
|
EUSA |
3.3 |
|
|
----------- |
|
Total |
45.4 |
|
Geographical Allocation |
% |
|
United States |
83 |
|
Europe |
17 |
|
Israel |
5 |
|
Australia |
2 |
|
Cash |
(7) |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted allocation |
% |
|
Quoted |
81 |
|
Unquoted |
26 |
|
Cash |
(7) |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
12 OCTOBER 2011